TORONTO, June 30, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (“Transition” or the “Company”) (Nasdaq:TTHI) (TSX:TTH) announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage (“ICH”) and traumatic brain injury (“TBI”). In pre-clinical studies, TT-301 has been shown to act by inhibiting the overproduction of inflammatory cytokines, such as interleukin-1 (IL-1Beta), tumour necrosis factor-alpha (TNF-Alpha), a key disease process associated with many inflammatory and degenerative diseases.
